This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Recursion (RXRX) Inks Neuroscience and Oncology Deal With Roche
by Zacks Equity Research
Recursion (RXRX) inks a collaboration with Roche to identify novel targets and advance medicines in areas of neuroscience and oncology indication. Shares rise.
Sanofi's (SNY) Filing for Rare Disease Drug Accepted by EMA
by Zacks Equity Research
The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.
Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19
by Zacks Equity Research
The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a headwind.
Novartis (NVS) Highlights Growth Profile at its R&D Day
by Zacks Equity Research
Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.
Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.
ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study
by Zacks Equity Research
ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.
4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio
by Zacks Equity Research
Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.
Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids
by Kinjel Shah
FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.
Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU
by Zacks Equity Research
Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.
Atea (AVIR) Plunges on Termination of Collaboration With Roche
by Zacks Equity Research
Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.
Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe
by Zacks Equity Research
Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.
AstraZeneca (AZN), Moderna's Heart Failure Study Successful
by Zacks Equity Research
AstraZeneca (AZN) and Moderna are developing an mRNA-based therapeutic to treat heart failure in patients undergoing coronary artery bypass surgery.
Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail
by Zacks Equity Research
Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.
Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm
by Zacks Equity Research
Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.
Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion
by Zacks Equity Research
Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.
AstraZeneca (AZN) Q3 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) surpasses third-quarter estimates for revenues while missing the same for earnings. The company retains 2021 guidance.
Epizyme (EPZM) Q3 Loss Wider Than Expected, Revenues Up
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss in the third quarter and revenues miss estimates. Nevertheless, the pipeline progress is encouraging.
Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
Puma (PBYI) Misses on Q3 Earnings, Cuts Sales View, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) reports lower-than-expected Q3 earnings and sales. It slashes 2021 Nerlynx sales guidance.
Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Prothena misses on earnings and revenues in the third quarter of 2021. Nevertheless, the company's progress with its AD pipeline is encouraging.
Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth
by Zacks Equity Research
Regeneron (REGN) beats on Q3 earnings while sales record strong year-over-year growth on the solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.
Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the third quarter. The company also raises revenues guidance for the year. Stock up in after-market trading.
Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Ionis (IONS) incurs wider-than-expected Q3 loss. The company maintains its top-and bottom-line guidance for 2021